Allogenic bone marrow transplantation with fludarabine/busulfan16 conditioning regimen and dasatinib maintenance therapy for elderly Philadelphia-positive acute/advanced leukemia patients

Posted by rob on February 25, 2010 under Uncategorized | Comments are off for this article

Therapeutic outcome of chronic myelogenous leukemia (CML) in advanced phases and of Philadelphia chromosome-positive (Ph+) acute leukemias remains dismal, even with tyrosine kinase inhibitors (TKIs) against Bcr-Abl or hematopoietic stem cell transplantation (HSCT) with maximally myeloablative conditioning (MAST). Especially, because patients over 55 years old are not eligible for MAST, the establishment of a treatment strategy for elderly patients with acute/advanced Ph+ leukemias has long been anticipated. We here present our experience with the use of fludarabine (Flu)/busulfan (Bu) 16 conditioning regimen (FB16) and dasatinib maintenance therapy following allogenic bone marrow transplantation (BMT) for two elderly patients with Ph+ acute/advanced leukemia. (Source: Leukemia Research)
More